Form 8-K - Current report:
SEC Accession No. 0001178913-24-003126
Filing Date
2024-09-24
Accepted
2024-09-24 07:10:23
Documents
17
Period of Report
2024-09-24
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K zk2432063.htm   iXBRL 8-K 49985
2 EXHIBIT 99.1 exhibit_99-1.htm EX-99.1 15383
7 image0.jpg GRAPHIC 20387
8 image1.jpg GRAPHIC 1963270
  Complete submission text file 0001178913-24-003126.txt   2983039

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA slxn-20240924.xsd EX-101.SCH 4623
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE slxn-20240924_def.xml EX-101.DEF 18263
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE slxn-20240924_lab.xml EX-101.LAB 27748
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE slxn-20240924_pre.xml EX-101.PRE 20505
20 EXTRACTED XBRL INSTANCE DOCUMENT zk2432063_htm.xml XML 6576
Mailing Address 2 HAMAYAN STREET MODIIN-MACCABIM-REUT L3 7177871
Business Address 2 HAMAYAN STREET MODIIN-MACCABIM-REUT L3 7177871 972-8-6286005
Silexion Therapeutics Corp (Filer) CIK: 0002022416 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42253 | Film No.: 241317535
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)